Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

TAMPA — Florida’s top health official blasted the manufacturer’s of mRNA COVID-19 vaccines and wants the federal government to do more to help those he described as the “vaccine injured.” Florida ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

When ticks bite us, they release thousands of proteins through their saliva. Could a vaccine for the right ones stop ticks ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...